Disruption! Everything is changing: BioNxt Solutions, BioNTech, Bio-Rad Laboratories

BioNTech continues to benefit from the mRNA revolution

The ongoing success of BioNTech demonstrates that innovation can pay off. Although the Company has been generating less and less revenue from its COVID-19 vaccine for some time now, thanks to its pioneering work at the time, the Mainz-based company now has numerous potential blockbusters in its portfolio. BioNTech is also demonstrating that even potential can be turned into revenue: its latest milestone is a major out-licensing agreement with Bristol Myers Squibb for the bispecific antibody BNT327. Bristol Myers Squibb will pay USD 1.5 billion upfront and up to USD 7.6 billion in milestone payments based on success. Both companies will jointly develop and commercialize BNT327, enabling BioNTech to accelerate its oncology portfolio with a strong partner. In addition, BioNTech will expand in June 2025 through the acquisition of German mRNA pioneer CureVac, a move that is likely to strengthen its own mRNA cancer platform further. To take over its Swabian competitor, BioNTech is paying USD 1.25 billion in its own shares – without the mRNA successes during the COVID-19 pandemic, the Mainz-based company would most likely not have had this acquisition currency** at its disposal.

Bio-Rad Laboratories suffers from weak sales

Diagnostics specialist Bio-Rad Laboratories continues to benefit from its strong reputation. Bio-Rad is a global provider of life science and clinical diagnostics solutions. The Company develops and sells laboratory equipment, reagents, and software - ranging from PCR systems and quality control tools to blood typing and life science research tools. Bio-Rad's products are considered the gold standard in many laboratories and clinics, which has provided the Company with a stable foundation for decades. Recently, however, the reluctance of public laboratories has impacted the figures: In the first quarter of 2025, revenue fell by 4.2% to USD 585 million. This illustrates that even established companies can suffer from weak sales when major innovations fail to materialize.

BioNxt: Innovative dosage forms as a lucrative niche

With cutting-edge innovations and a goal-oriented platform approach, the Canadian biotech company BioNxt Solutions, which operates its central laboratory in Munich, aims to make a strong market entry. BioNxt develops innovative drug delivery systems, such as dissolvable drug films for sublingual use and transdermal drug patches. The biotech company's projects also focus on the development of patient-centered therapy solutions.

Manufacturing its own active ingredients is not a high priority for BioNxt. The reason is that the Company focuses on increasing therapy adherence and patient comfort with proven active ingredients. This is achieved, for example, by administering active ingredients via patches or active ingredient films. In the coming months, the Company will conduct a bioequivalence study** for BNT23001, a cladribine formulation in the form of a thin film for the treatment of multiple sclerosis. The aim is to demonstrate its effectiveness to potential partners and initiate further strategic partnerships, for example, in the field of anti-aging medicine. Comprehensive patent protection for its proprietary technology is already in place.

Advantages in patient care: Improving crucial details

Unlike major technology leaders researching mRNA processes or innovative laboratory equipment, BioNxt operates in a niche market. However, this niche is extremely promising. Adherence is one of the most critical factors for successful therapies, referring to how consistently patients follow their prescribed therapies. If effective dosage forms make it easier to take medication regularly, this reduces patient suffering and costs. In addition, the method of drug delivery can also influence the dose or dosage interval – this may allow expensive active ingredients to be used more efficiently, and treatment can become simpler for patients. This is the case, for example, when instead of taking tablets three times a day, a patient may only need to apply a single transdermal patch. These types of innovations are also highly valuable in typical care settings, such as home nursing, where caregivers administer medication once a day. If a patch is applied during the visit, medication adherence for the entire day is ensured. In contrast, if patients need to take multiple tablets throughout the day on their own, the risk of missed doses remains high.

The share price performance over the past few months indicates that BioNXt has potential in the areas of multiple sclerosis and anti-ageing. Despite the share price gains, BioNxt's market capitalization remains only slightly above EUR 40 million. If the bioequivalence study on cladribine for multiple sclerosis shows good efficacy, this could have a signaling effect for similar active ingredients and lead to new collaborations.